Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population
Purpose of Review Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potenti...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2022-03, Vol.24 (3), p.351-362 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 362 |
|---|---|
| container_issue | 3 |
| container_start_page | 351 |
| container_title | Current oncology reports |
| container_volume | 24 |
| creator | Kishore, Sirish A. Bajwa, Raazi Van Doren, Layla Wilkins, Cy O’Sullivan, Gerard J. |
| description | Purpose of Review
Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be reviewed in this article.
Recent Findings
The recent NCCN guidelines recommend endovascular therapy in patients eligible for therapeutic anticoagulation who present with life-, organ-, or limb-threatening thrombosis. However, symptomatic
non-life-threatening
VTE can negatively affect QOL and physical function, both of which have prognostic implications in the cancer population. Endovascular therapies have been shown to improve physical function and QOL in prospective trials performed in a non-oncologic patient population as well as small retrospective studies in the cancer population.
Summary
In addition to treating life- and limb-threatening thrombosis, endovascular therapy for VTE can improve QOL and physical function in comparison to anticoagulation alone. Prospective trials are warranted to assess the benefit of endovascular therapy for quality of life-years, performance status, and overall survival in the oncologic patient population. |
| doi_str_mv | 10.1007/s11912-022-01191-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2626227749</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634287590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-a07134ee77a37639fa113cc0254adda758ea344378493f805b6b778c75ea16fd3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolD4ARYoEhs2AT-SOFmiUh5SUbsorJAsx5m0qRK72AkSf49DCkgsWIxmpDn32nMROiP4imDMrx0hGaEhpr76MUz20BGJWRQmNMn2-5mykPEMj9CxcxuMKcYpPkQjFhOa8ZQeodepLsy7dKqrpQ2epJYraEC3gSmDF9Cmc8FybU2TG_BVVyq4rRxIB0Glg3YNwVwrU5uVXyxkW_XKhdl6s7Yy-gQdlLJ2cLrrY_R8N11OHsLZ_P5xcjMLFeNxG0rMCYsAOJeMJywrJSFMKUzjSBaF5HEKkkUR42mUsTLFcZ7knKeKxyBJUhZsjC4H3601bx24VjSVU1DXUoO_QFCfB6Wce_kYXfxBN6az2v_OUyyiKY8z7Ck6UMoa5yyUYmurRtoPQbDosxdD9sJnL76yF4kXne-su7yB4kfyHbYH2AA4v9IrsL9v_2P7CcBxjnU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634287590</pqid></control><display><type>article</type><title>Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Kishore, Sirish A. ; Bajwa, Raazi ; Van Doren, Layla ; Wilkins, Cy ; O’Sullivan, Gerard J.</creator><creatorcontrib>Kishore, Sirish A. ; Bajwa, Raazi ; Van Doren, Layla ; Wilkins, Cy ; O’Sullivan, Gerard J.</creatorcontrib><description>Purpose of Review
Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be reviewed in this article.
Recent Findings
The recent NCCN guidelines recommend endovascular therapy in patients eligible for therapeutic anticoagulation who present with life-, organ-, or limb-threatening thrombosis. However, symptomatic
non-life-threatening
VTE can negatively affect QOL and physical function, both of which have prognostic implications in the cancer population. Endovascular therapies have been shown to improve physical function and QOL in prospective trials performed in a non-oncologic patient population as well as small retrospective studies in the cancer population.
Summary
In addition to treating life- and limb-threatening thrombosis, endovascular therapy for VTE can improve QOL and physical function in comparison to anticoagulation alone. Prospective trials are warranted to assess the benefit of endovascular therapy for quality of life-years, performance status, and overall survival in the oncologic patient population.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-022-01191-6</identifier><identifier>PMID: 35129782</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Anticoagulants - therapeutic use ; Cancer ; Cardiovascular system ; Clinical trials ; Endovascular Procedures - adverse effects ; Humans ; Interventional Oncology (DC Madoff ; Medicine ; Medicine & Public Health ; Morbidity ; Neoplasms - drug therapy ; Oncology ; Patients ; Population studies ; Prospective Studies ; Quality of Life ; Retrospective Studies ; Section Editor ; Thromboembolism ; Thrombosis ; Topical Collection on Interventional Oncology ; Venous Thromboembolism - drug therapy ; Venous Thromboembolism - therapy ; Venous Thrombosis - epidemiology ; Venous Thrombosis - etiology ; Venous Thrombosis - therapy</subject><ispartof>Current oncology reports, 2022-03, Vol.24 (3), p.351-362</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022</rights><rights>2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</rights><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-a07134ee77a37639fa113cc0254adda758ea344378493f805b6b778c75ea16fd3</citedby><cites>FETCH-LOGICAL-c375t-a07134ee77a37639fa113cc0254adda758ea344378493f805b6b778c75ea16fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-022-01191-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-022-01191-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35129782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kishore, Sirish A.</creatorcontrib><creatorcontrib>Bajwa, Raazi</creatorcontrib><creatorcontrib>Van Doren, Layla</creatorcontrib><creatorcontrib>Wilkins, Cy</creatorcontrib><creatorcontrib>O’Sullivan, Gerard J.</creatorcontrib><title>Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of Review
Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be reviewed in this article.
Recent Findings
The recent NCCN guidelines recommend endovascular therapy in patients eligible for therapeutic anticoagulation who present with life-, organ-, or limb-threatening thrombosis. However, symptomatic
non-life-threatening
VTE can negatively affect QOL and physical function, both of which have prognostic implications in the cancer population. Endovascular therapies have been shown to improve physical function and QOL in prospective trials performed in a non-oncologic patient population as well as small retrospective studies in the cancer population.
Summary
In addition to treating life- and limb-threatening thrombosis, endovascular therapy for VTE can improve QOL and physical function in comparison to anticoagulation alone. Prospective trials are warranted to assess the benefit of endovascular therapy for quality of life-years, performance status, and overall survival in the oncologic patient population.</description><subject>Anticoagulants - therapeutic use</subject><subject>Cancer</subject><subject>Cardiovascular system</subject><subject>Clinical trials</subject><subject>Endovascular Procedures - adverse effects</subject><subject>Humans</subject><subject>Interventional Oncology (DC Madoff</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Morbidity</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Patients</subject><subject>Population studies</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Retrospective Studies</subject><subject>Section Editor</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Topical Collection on Interventional Oncology</subject><subject>Venous Thromboembolism - drug therapy</subject><subject>Venous Thromboembolism - therapy</subject><subject>Venous Thrombosis - epidemiology</subject><subject>Venous Thrombosis - etiology</subject><subject>Venous Thrombosis - therapy</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kMtOwzAQRS0EolD4ARYoEhs2AT-SOFmiUh5SUbsorJAsx5m0qRK72AkSf49DCkgsWIxmpDn32nMROiP4imDMrx0hGaEhpr76MUz20BGJWRQmNMn2-5mykPEMj9CxcxuMKcYpPkQjFhOa8ZQeodepLsy7dKqrpQ2epJYraEC3gSmDF9Cmc8FybU2TG_BVVyq4rRxIB0Glg3YNwVwrU5uVXyxkW_XKhdl6s7Yy-gQdlLJ2cLrrY_R8N11OHsLZ_P5xcjMLFeNxG0rMCYsAOJeMJywrJSFMKUzjSBaF5HEKkkUR42mUsTLFcZ7knKeKxyBJUhZsjC4H3601bx24VjSVU1DXUoO_QFCfB6Wce_kYXfxBN6az2v_OUyyiKY8z7Ck6UMoa5yyUYmurRtoPQbDosxdD9sJnL76yF4kXne-su7yB4kfyHbYH2AA4v9IrsL9v_2P7CcBxjnU</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Kishore, Sirish A.</creator><creator>Bajwa, Raazi</creator><creator>Van Doren, Layla</creator><creator>Wilkins, Cy</creator><creator>O’Sullivan, Gerard J.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20220301</creationdate><title>Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population</title><author>Kishore, Sirish A. ; Bajwa, Raazi ; Van Doren, Layla ; Wilkins, Cy ; O’Sullivan, Gerard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-a07134ee77a37639fa113cc0254adda758ea344378493f805b6b778c75ea16fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anticoagulants - therapeutic use</topic><topic>Cancer</topic><topic>Cardiovascular system</topic><topic>Clinical trials</topic><topic>Endovascular Procedures - adverse effects</topic><topic>Humans</topic><topic>Interventional Oncology (DC Madoff</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Morbidity</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Patients</topic><topic>Population studies</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Retrospective Studies</topic><topic>Section Editor</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Topical Collection on Interventional Oncology</topic><topic>Venous Thromboembolism - drug therapy</topic><topic>Venous Thromboembolism - therapy</topic><topic>Venous Thrombosis - epidemiology</topic><topic>Venous Thrombosis - etiology</topic><topic>Venous Thrombosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kishore, Sirish A.</creatorcontrib><creatorcontrib>Bajwa, Raazi</creatorcontrib><creatorcontrib>Van Doren, Layla</creatorcontrib><creatorcontrib>Wilkins, Cy</creatorcontrib><creatorcontrib>O’Sullivan, Gerard J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kishore, Sirish A.</au><au>Bajwa, Raazi</au><au>Van Doren, Layla</au><au>Wilkins, Cy</au><au>O’Sullivan, Gerard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>24</volume><issue>3</issue><spage>351</spage><epage>362</epage><pages>351-362</pages><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>Purpose of Review
Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be reviewed in this article.
Recent Findings
The recent NCCN guidelines recommend endovascular therapy in patients eligible for therapeutic anticoagulation who present with life-, organ-, or limb-threatening thrombosis. However, symptomatic
non-life-threatening
VTE can negatively affect QOL and physical function, both of which have prognostic implications in the cancer population. Endovascular therapies have been shown to improve physical function and QOL in prospective trials performed in a non-oncologic patient population as well as small retrospective studies in the cancer population.
Summary
In addition to treating life- and limb-threatening thrombosis, endovascular therapy for VTE can improve QOL and physical function in comparison to anticoagulation alone. Prospective trials are warranted to assess the benefit of endovascular therapy for quality of life-years, performance status, and overall survival in the oncologic patient population.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35129782</pmid><doi>10.1007/s11912-022-01191-6</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2022-03, Vol.24 (3), p.351-362 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2626227749 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anticoagulants - therapeutic use Cancer Cardiovascular system Clinical trials Endovascular Procedures - adverse effects Humans Interventional Oncology (DC Madoff Medicine Medicine & Public Health Morbidity Neoplasms - drug therapy Oncology Patients Population studies Prospective Studies Quality of Life Retrospective Studies Section Editor Thromboembolism Thrombosis Topical Collection on Interventional Oncology Venous Thromboembolism - drug therapy Venous Thromboembolism - therapy Venous Thrombosis - epidemiology Venous Thrombosis - etiology Venous Thrombosis - therapy |
| title | Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A40%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endovascular%20Management%20of%20Venous%20Thromboembolic%20Disease%20in%20the%20Oncologic%20Patient%20Population&rft.jtitle=Current%20oncology%20reports&rft.au=Kishore,%20Sirish%20A.&rft.date=2022-03-01&rft.volume=24&rft.issue=3&rft.spage=351&rft.epage=362&rft.pages=351-362&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-022-01191-6&rft_dat=%3Cproquest_cross%3E2634287590%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634287590&rft_id=info:pmid/35129782&rfr_iscdi=true |